XPR – Lifestyle Demo
Author:
Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
March 17, 2026
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results
March 12, 2026